

## **MOIDX OPEN MEETING AGENDA**

A CELERIAN GROUP COMPANY

Date:	October 9, 2023
Meeting Time:	2 – 3:25 p.m. ET
Location:	Microsoft Teams Meeting: Call in 803-393-7908 Meeting ID: 242 118 330 287 Passcode: NAQinf or Click here to join the meeting or Phone Conference ID: 338 705 485# (audio only)
Presenters:	
2:00 pm to 2:05 p.m.	Opening Remarks- Dr. Angella Charnot-Katsikas
2:05 p.m. to 2:20 p.m.	MolDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers DL39636  Ashley E. Ross, MD, PHD, Associate Professor Urology, Clinical Director Polsky Urologic Institute
2:20 p.m. to 2:35 p.m.	MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy DL39654 Ehab Billatos, MD, Assistant Professor of Medicine, Director of Inpatient Pulmonary Clinical Services, Director of Bronchoscopy, Boston University School of Medicine
2:35 p.m. to 2:50 p.m.	MoIDX: Molecular Testing for Risk Stratification of Thyroid Nodules DL39646  Paul W. Ladenson, MD, John Eager Howard Professor of Endocrinology & Metabolism,  Professor of Medicine, Pathology, and Oncology, Johns Hopkins University School of Medicine
2:50 p.m. to 3:05 p.m.	MolDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy DL39654 Paul Pagano, PhD, CEO LungLifeAI
3:05 p.m. to 3:20 p.m.	MoIDX: Gene Expression Profile Tests for Decision-Making in Castration Resistant and Metastatic Prostate Cancers DL39636  MoIDX: Molecular Biomarkers for Risk Stratification of Indeterminate Pulmonary Nodules Following Bronchoscopy DL39654  MoIDX: Molecular Testing for Risk Stratification of Thyroid Nodules DL39646  John Leite, PHD, Chief Commercial Officer, CLIA
3:20 p.m. to 3:25 p.m.	Closing Remarks